Press coverage about Kadmon (NYSE:KDMN) has been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kadmon earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.0114874602622 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Major Biopharma Catalysts on February’s FDA Calendar (247wallst.com)
- Kadmon Holdings Inc (KDMN) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Shares of Kadmon Holdings, Inc. (KDMN) are worth at $5.26 – Wall Street Morning (wallstreetmorning.com)
- $3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter (americanbankingnews.com)
Several research analysts have commented on the company. Zacks Investment Research downgraded Kadmon from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Kadmon in a report on Friday, November 17th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Kadmon presently has an average rating of “Hold” and a consensus target price of $8.65.
Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million during the quarter, compared to analyst estimates of $5.69 million. During the same quarter in the previous year, the company earned ($4.24) EPS. The company’s revenue for the quarter was down 60.0% on a year-over-year basis. analysts expect that Kadmon will post -1.62 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2018/02/07/kadmon-kdmn-earns-media-sentiment-rating-of-0-03.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.